Latest News
Theralase Technologies Inc.
- TSXV:TLT Forum Post | knoxt-37158455 | TOP BULLBOARDS , We are # 1 . | Theralase Technologies Inc
- What Did Theralase (TSXV:TLT) Reveal in Its Interim Ruvidar Data?
- What Do Theralase’s (TSXV:TLT) Interim Ruvidar Results Show?
- Theralase Provides Bladder Cancer Clinical Study Update
- Purchase/sale of investments (net) of Theralase Technologies Inc. – TSXV:TLT
- Theralase Technologies Inc Warrant 2026-20.05.2031 on Theralase Tech Estimates – TSXV:TLT.WT
- Theralase Technologies’ C$3.6 Million Financing Supports Clinical-Stage Development (TSXV:TLT)
- Theralase® Technologies to Present Ruvidar® and Rutherrin® Pipeline at 2026 ThinkEquity Conference in New York
- Theralase(R) to Present at ThinkEquity Conference
- Theralase to present cancer-fighting drug progr...
- Theralase Technologies (TSXV:TLT) Stock Rises 5.71% as Ruvidar Bladder Cancer Study Nears Key Regulatory Milestone
Headlines from the last 30 days, linking to the original publishers. See all market news →